- Shares of Cyclacel Pharmaceuticals, Inc. CYCC surged 34.8% after the company announced a collaboration agreement with the University of Edinburgh to study its CDK Inhibitors to diminish runaway inflammation in COVID-19.
- Shares of NovaBay Pharmaceuticals, Inc. NBY soared 69.7% after the company signed an agreement to distribute coronavirus antibody rapid point-of-care test to U.S. healthcare professionals.
- Shares of Exelixis, Inc. EXEL rose 21.3% after the company announced the results from its Phase 3 CheckMate-9ER Trial, which met the primary endpoint.
- Shares of Co-Diagnostics, Inc. CODX gained 11.4% after the company said its COVID-19 test orders in the United States have continued to rise.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Exelixis, Inc. (EXEL) : Free Stock Analysis Report
Cyclacel Pharmaceuticals, Inc. (CYCC) : Free Stock Analysis Report
NovaBay Pharmaceuticals, Inc. (NBY) : Free Stock Analysis Report
Co-Diagnostics, Inc. (CODX) : Free Stock Analysis Report
To read this article on Zacks.com click here.